The global and Korean pharmaceutical industries are focusing on securing Targeted Protein Degradation (TPD) technology, which has emerged following the success of Antibody-Drug Conjugates (ADCs). Recently, major global pharmaceutical companies such as Pfizer, Novartis, and Eli Lilly have successfully acquired TPD technologies, marking TPD as a new anti-cancer drug development strategy, following targeted therapies, immune checkpoint inhibitors, and ADCs. Korean pharmaceutical and biotech industries are also exploring the potential of TPD drug development and have achieved successful technology transfers.

According to industry sources on September 3rd, several Korean biopharmaceutical companies, including Y